UCB is committed to improving care and outcomes for patients across the axial spondyloarthritis spectrum of disease. So, for Spondyloarthritis Awareness Month, we’re shining a spotlight on Non-Radiographic Axial Spondyloarthritis (nr-axSpA).

Earlier this week, researchers from across UCB met in Washington, D.C. for the PhRMA Researcher Fly-In. While on Capitol Hill, the UCB team visited the offices of Representatives Doug Collins, Lucy McBath, and David Price, and Senators Johnny Isakson, Richard Burr, and Thom Tillis and walked their staff through the 15-year journey (on average) of how a new medicine is discovered, developed, and delivered at UCB. Each researcher, representing a different part of the drug development process, shared their personal stories about why they’re motivated each day to continue to innovate for patients.

We believe our ability to continue to innovate and create value for patients now and in the future will increasingly depend on our positive contributions to environmental sustainability.

Brussels (Belgium) & Atlanta, Georgia (U.S.) - April 1, 2019: UCB announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter requesting additional information to complete the review of the New Drug Application for midazolam nasal spray, a rescue treatment for acute repetitive seizures (ARS, also known as seizure clusters) in patients with epilepsy. UCB acquired the rights to midazolam nasal spray from Proximagen in June 2018.

• Patients living with non-radiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatment

• FDA approval was based on the C-AXSPAND Phase 3 study in adults with non-radiographic axial spondyloarthritis, which demonstrated rapid and major improvement response with CIMZIA compared to placebo. Patients remained on common background medications, which could be adjusted at any point during the study

At UCB, we are inspired by patients and driven by science to deliver what patients value. We are committed to continuously working to advance science and embrace new knowledge — leading to the discovery of new solutions that help patients achieve their goals.

2018 marked the 90th anniversary of UCB. Since our creation in 1928, UCB has been characterized by a strong entrepreneurial spirit, determination and resilience, long term views, and a strong belief science and innovation would improve humanity.

Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study